Tukysa® (tucatinib) – New indication
January 19, 2023 - Seagen announced the FDA approval of Tukysa (tucatinib), in combination with trastuzumab, for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Top